Ocaliva appears to fit FDA's definition of a 'dangling' accelerated approval - when prespecified postmarketing trials do not confirm benefit but marketing continues. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
